ORIC PHARMACEUTICALS, INC. Payments to Acquire Investments
ORIC PHARMACEUTICALS, INC. (ORIC) reported Payments to Acquire Investments of $125.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2026-06-30 was $47.78M, a 61.58% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2026-03-31 was $77.97M, a 20.58% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2025-12-31 was $45.29M, a 30.79% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. payments to acquire investments for the quarter ending 2025-09-30 was $165.50M, a 206.41% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2025 was $399.82M, a 58.71% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2024 was $251.92M, a 5.30% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2023 was $239.24M, a 0.47% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. payments to acquire investments for fiscal 2022 was $238.12M, a 242.00% increase from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $125.75M 10-Q · filed 2026-08-03 | $171.04M derived: sum of 3 quarters · filed 2026-08-03 | $336.54M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $77.97M 10-Q · filed 2026-05-04 | $123.26M derived: sum of 2 quarters · filed 2026-05-04 | $288.76M derived: sum of 3 quarters · filed 2026-05-04 | $413.13M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $45.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $210.79M derived: sum of 2 quarters · filed 2026-02-23 | $335.16M derived: sum of 3 quarters · filed 2026-08-03 | $399.82M 10-K · filed 2026-02-23 |
| 2025-09-30 | $165.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $289.87M derived: sum of 2 quarters · filed 2026-08-03 | $354.53M 10-Q · filed 2025-11-13 | $389.16M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $124.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $189.03M 10-Q · filed 2026-08-03 | $223.66M derived: sum of 3 quarters · filed 2026-08-03 | $277.67M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $64.66M 10-Q · filed 2026-05-04 | $99.29M derived: sum of 2 quarters · filed 2026-05-04 | $153.30M derived: sum of 3 quarters · filed 2026-05-04 | $202.19M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $34.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $88.64M derived: sum of 2 quarters · filed 2026-02-23 | $137.53M derived: sum of 3 quarters · filed 2026-02-23 | $251.92M 10-K · filed 2026-02-23 |
| 2024-09-30 | $54.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $102.90M derived: sum of 2 quarters · filed 2025-11-13 | $217.29M 10-Q · filed 2025-11-13 | $246.26M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $48.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $163.28M 10-Q · filed 2025-08-12 | $192.25M derived: sum of 3 quarters · filed 2025-08-12 | $303.24M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $114.39M 10-Q · filed 2025-05-05 | $143.37M derived: sum of 2 quarters · filed 2025-05-05 | $254.35M derived: sum of 3 quarters · filed 2025-05-05 | $310.25M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $28.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $139.96M derived: sum of 2 quarters · filed 2025-02-18 | $195.86M derived: sum of 3 quarters · filed 2025-02-18 | $239.24M 10-K · filed 2025-02-18 |
| 2023-09-30 | $110.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $166.89M derived: sum of 2 quarters · filed 2024-11-12 | $210.27M 10-Q · filed 2024-11-12 | $241.91M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $55.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $99.28M 10-Q · filed 2024-08-12 | $130.92M derived: sum of 3 quarters · filed 2024-08-12 | $191.94M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $43.39M 10-Q · filed 2024-05-06 | $75.02M derived: sum of 2 quarters · filed 2024-05-06 | $136.04M derived: sum of 3 quarters · filed 2024-05-06 | $181.57M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $31.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $92.65M derived: sum of 2 quarters · filed 2024-03-11 | $138.19M derived: sum of 3 quarters · filed 2024-03-11 | $238.12M 10-K · filed 2024-03-11 |
| 2022-09-30 | $61.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $106.56M derived: sum of 2 quarters · filed 2023-11-06 | $206.49M 10-Q · filed 2023-11-06 | $243.25M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $45.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $145.47M 10-Q · filed 2023-08-10 | $182.23M derived: sum of 3 quarters · filed 2023-08-10 | $189.93M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $99.94M 10-Q · filed 2023-05-08 | $136.70M derived: sum of 2 quarters · filed 2023-05-08 | $144.39M derived: sum of 3 quarters · filed 2023-05-08 | $144.39M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $36.76M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $44.45M derived: sum of 2 quarters · filed 2023-03-16 | $44.45M derived: sum of 3 quarters · filed 2023-03-16 | $69.63M 10-K · filed 2023-03-16 |
| 2021-09-30 | $7.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $7.70M derived: sum of 2 quarters · filed 2022-11-07 | $32.87M 10-Q · filed 2022-11-07 | $133.71M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $25.17M 10-Q · filed 2022-08-11 | $126.02M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $25.17M 10-Q · filed 2022-05-09 | $126.02M derived: sum of 2 quarters · filed 2022-05-09 | ||
| 2020-12-31 | $100.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $225.49M 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $124.64M 10-Q · filed 2021-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |